Regulus Therapeutics Inc. (NASDAQ:RGLS) shares were down 4% during trading on Thursday . The company traded as low as $3.31 and last traded at $3.34, with a volume of 578,829 shares changing hands. The stock had previously closed at $3.48.

A number of research analysts have recently commented on RGLS shares. BMO Capital Markets started coverage on Regulus Therapeutics in a research report on Monday, April 11th. They set an “outperform” rating and a $16.00 target price for the company. Zacks Investment Research downgraded Regulus Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, May 6th. FBR & Co reiterated a “buy” rating and set a $30.00 target price on shares of Regulus Therapeutics in a research report on Thursday, June 2nd. Cowen and Company reiterated a “buy” rating on shares of Regulus Therapeutics in a research report on Wednesday, June 8th. Finally, Chardan Capital started coverage on Regulus Therapeutics in a research report on Wednesday, April 13th. They set a “buy” rating and a $15.00 target price for the company. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Regulus Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $10.42.

The firm’s 50 day moving average is $5.17 and its 200-day moving average is $6.41. The company’s market cap is $181.04 million.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.07. Equities research analysts forecast that Regulus Therapeutics Inc. will post ($1.54) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Regulus Therapeutics stock. Wells Fargo & Company MN raised its position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) by 3.3% during the fourth quarter, Holdings Channel reports. The firm owned 272,652 shares of the biopharmaceutical company’s stock after buying an additional 8,615 shares during the period. Wells Fargo & Company MN owned 0.52% of Regulus Therapeutics worth $2,378,000 at the end of the most recent reporting period.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.